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PGP-UK ConsortiumAbstract
Background: Molecular analyses such as whole-genome sequencing have become routine and are expected to be
transformational for future healthcare and lifestyle decisions. Population-wide implementation of such analyses is,
however, not without challenges, and multiple studies are ongoing to identify what these are and explore how
they can be addressed.
Methods: Defined as a research project, the Personal Genome Project UK (PGP-UK) is part of the global PGP network
and focuses on open data sharing and citizen science to advance and accelerate personalized genomics and medicine.
Results: Here we report our findings on using an open consent recruitment protocol, active participant involvement,
open access release of personal genome, methylome and transcriptome data and associated analyses, including 47
new variants predicted to affect gene function and innovative reports based on the analysis of genetic and epigenetic
variants. For this pilot study, we recruited 10 participants willing to actively engage as citizen scientists with the project.
In addition, we introduce Genome Donation as a novel mechanism for openly sharing previously restricted data and
discuss the first three donations received. Lastly, we present GenoME, a free, open-source educational app suitable for
the lay public to allow exploration of personal genomes.
Conclusions: Our findings demonstrate that citizen science-based approaches like PGP-UK have an important role to
play in the public awareness, acceptance and implementation of genomics and personalized medicine.
Keywords: Personal genomics, Open consent, Open access, Genome donation, Genome reports, Genome app, Citizen
scienceBackground
The sequencing of the first human genome in 2001 [1, 2]
catalysed a revolution in technology development, resulting
in around 1 million human genomes having been
sequenced to date at ever decreasing costs [3]. This still
expanding effort is underpinned by a widespread consen-
sus among researchers, clinicians and politicians that
‘omics’ in one form or another will transform biomedical
research, healthcare and lifestyle decisions. For this trans-
formation to happen successfully, the provision of choices
that accommodate the differing needs and priorities of sci-
ence and society are necessary. The clinical need is being* Correspondence: s.beck@ucl.ac.uk
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(http://creativecommons.org/publicdomain/zeaddressed by efforts such as the Genomics England 100 K
Genome Project [4] and the US Precision Medicine Initia-
tive [5] (recently renamed to ‘All of Us’) whilst the public’s
desire for direct-to-consumer genetic testing is met by a
growing number of companies [6]. However, little of the
data from these sources are being made available for re-
search under open access which, in the past, has been a
driving force for discovery and tool development [7]. This
important research need for unrestricted access to data
was first recognised by the Human Genome Project and
implemented in the ‘Bermuda Principles’ [8]. The concept
proved highly successful and was developed further by per-
sonal genome projects such as PGP [9–12] and iPOP [13]
and, more recently, has also been adopted by some medical
genome projects like TXCRB [14] and MSSNG [11] the
latter of which uses a variant of registered access [15].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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which was founded by George Church and colleagues at
Harvard University. The Network currently comprises five
active PGPs in the United States (Boston, since 2005),
Canada (Toronto, since 2012), United Kingdom (London,
since 2013), Austria (Vienna, since 2014) and China
(Shanghai, since 2017). In Europe, PGP-UK was the first
project to implement the open consent framework [16] pio-
neered by the Harvard PGP for participant recruitment and
data release. Under this ethics approved framework,
PGP-UK participants agree for their omics and associated
trait, phenotype and health data to be deposited in public
databases under open access. Despite the risks associated
with sharing identifiable personal information, PGP-UK has
received an enthusiastic response by prospective partici-
pants and even had to pause enrolment after more than
10,000 people registered interest within a month of launch-
ing the project. The rigorous enrolment procedure includes
a single exam to document that the risks as well as the ben-
efits of open data sharing have been understood by pro-
spective participants and the first 1,000 have been allowed
to fully enrol and consent.
Taking advantage of PGP-UK being a hybrid between a
research and a citizen science project, we (the researchers
and participants) describe here our initial findings from the
pilot study of the first 10 participants and the resulting
variant reports. Specifically, this includes the description of
variants identified in the participants’ genomes and methy-
lomes as well as our interpretation relating to ancestry, pre-
dicted traits, self-reported phenotypes and environmental
exposures. Citizen Science and Citizen Scientist has many
definitions and facets [17]. As examples of citizen science,
which we define here as activity that encourages members
of the public to participate in research by taking on the
roles of both subject and scientist [18], we describe the first
three genome donations received by PGP-UK and we
present GenoME, the first app developed as an educational
tool for the lay public to better understand personalized
and medical genomics. Fronted by four PGP-UK ambassa-
dors, GenoME’s audio-visual effects provide an intuitive
interface to learn about genome interpretation in the
contexts outlined above. Mobile apps have become the
method of choice for the public to engage with complex
information and processes such as navigation using global
positioning systems, internet shopping/banking and a
variety of educational and health-related activities [19]. The
open nature of the PGP-UK data make them an attractive
resource for investigating interactions between genomics,
environmental exposures, health-related behaviours and
outcomes in health and disease. For example, the MedSeq
Project recently trialled the impact of whole-genome
sequencing (WGS) on the primary care and outcomes of
healthy adult patients and identified sample size as one of
the limiting factors [20].Methods
Ethics
The research conformed to the requirements of the Dec-
laration of Helsinki, UK national laws and to UK regulatory
requirements for medical research. All participants were
informed, consented, subjected to an online entrance exam
and enrolled as described on the PGP-UK sign-up web site
(www.personalgenomes.org.uk/sign-up). The study was
approved by the UCL Research Ethics Committee (ID
Number 4700/001) and is subject to annual reviews and
renewals. PGP-UK participants uk35C650, uk33D02F,
uk481F67 and uk4CA868 all self-identified and consented
for their names, photos, videos and data to be used in the
manuscript and GenoME app.
Genome donations
Ethics approval for PGP-UK to receive genomes, exomes
and genotypes (e.g. 23andMe) and associated data
generated elsewhere was obtained from the UCL Research
Ethics Committee through an amendment of ID Number
4700/001. Enrolment in PGP-UK is accepted as proof that
prospective donors have been adequately informed and
have understood the risks of holding and donating their
genome and associated data. Equal to regular participants,
donors agree for their data and associated reports to be
made publicly available under open access by PGP-UK.
Once a genome donation has been received, the data are
processed and reports produced as for genomes generated
by PGP-UK. Donors are also eligible to provide samples
for the generation of additional data and reports as imple-
mented here for 450K methylome analysis.
Participant input and communication
The interests of the pilot participants were considered in
two ways. First, through personal telephone conversations
at the beginning of the project and through in-person/
skype meetings at the completion stage of their genome
and methylome reports. Examples of expressed interests
and motivations for participating are included in the
ambassador’s videos in the GenoME app. Second, through
social media and communications accounts on a range of
public platforms (Twitter, Facebook, YouTube and
WordPress; see LINKs, PGP-UK social media) which can
be viewed, followed, and subscribed to by participants and
members of the public. These media provide different
platforms for participants to communicate their wishes or
concerns and aim to increase public awareness of PGP-UK,
personal genomics and citizen science, consequently
engaging participants and members of the public further in
developments relating to PGP-UK and encouraging
involvement as citizen scientists. Through these platforms,
updates on PGP-UK activity, research and events can be
published directly to the public, alongside the sharing of
additional content to inform and educate the public in
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posts authored by participant citizen scientists can be
viewed in the PGP-UK blog. The communication platforms
are complemented by the PGP-UK YouTube channel as a
more visual and engaging form of communication.
Through Twitter and Facebook, short and accessible posts
are published as frequent updates on PGP-UK which regu-
larly link to the blogs and videos on other platforms, as well
as relevant external content, for example journal articles, to
promote further engagement in scientific progress.Samples
Blood samples (2 × 4 ml) were taken by a medical doctor
at the UCL Hospital using EDTA Vacutainers (Becton
Dickinson). Saliva samples were collected using Oragene
OG-500 self-sampling kits (DNA Genotek). All samples
were processed and stored at the UCL/UCLH Biobank
for Studying Health and Disease (http://www.ucl.ac.uk/
human-tissue/hta-biobanks/UCL-Cancer-Institute) using
HTA-approved standard operating procedures (SOPs).Data generation and analysis
Whole-genome sequencing (WGS) was subcontracted
to the Kinghorn Centre for Clinical Genomics (Australia)
and conducted on an Illumina HiSeq X platform. Illumina
TruSeq Nano libraries were prepared according to SOPs and
sequenced to an average depth of 30×. The sequenced reads
were trimmed using TrimGalore (http://www.bioinforma-
tics.babraham.ac.uk/projects/trim_galore/) and mapped
against the hg19 (GRCh37) human reference genome using
the BWA-MEM algorithm from BWA v0.7.12 [21]. After re-
moving ambiguously mapped reads (MAPQ < 10) with
SAMtools 1.2 [22] and marking duplicated reads with Picard
1.130 (http://broadinstitute.github.io/picard/), genomic vari-
ants were called following the Genome Analysis toolkit
(GATK 3.4–46; https://software.broadinstitute.org/gatk/) best
practices, which involves local realignment around indels,
base quality score recalibration, variant calling using the
GATK HaplotyeCaller, variant filtering using the variant
quality scoring recalibration (VQSR) protocol, and genotype
refinement for high-quality identification of individual geno-
types. Additionally, variants of phenotypic interest identified
from SNPedia [23] that were not called using the above pipe-
line due to being identical to the human reference genome
(homozygous reference variants), were obtained by preselect-
ing a list of phenotypically interesting variants and requesting
the GATK HaplotypeCaller to emit genotypes on these
chromosomal locations. The WGS data (FASTQ and BAM
files) have been deposited in the European Nucleotide Arch-
ive (ENA) under accession number PRJEB24961. The variant
files (VCFs) have been deposited in the European Variant
Archive (EVA) under accession number PRJEB17529 and
linked to the Global Alliance for Genomics and Health(GA4GH) Beacon project (https://www.ebi.ac.uk/eva/
?GA4GH) under the same accession number.
Whole-genome bisulfite sequencing (WGBS) was
subcontracted to the National Genomics Infrastructure
Science for Life Laboratory (Sweden) and conducted on
an Illumina HiSeq X platform. Bisulfite conversion and
library preparation were carried out using a TruMethyl
Whole Genome Kit v2.1 (Cambridge Epigenetix, now
marketed by NuGEN) and libraries sequenced to an
average depth of 15×. The resulting FASTQ files were
analysed using GEMBS [24]. As reported previously [25],
WGBS on the Illumina HiSeq X platform is not straight-
forward as the data are of inferior quality to those that
can be obtained on other HiSeq or NovaSeq platforms.
In our case, the average unique mapping quality was
63.86% for paired-end (PE) and 86.18% for single-end
(SE, forward) reads as assessed with GEMBS [24]. The
WGBS data have been deposited in ENA under
accession number PRJEB24961.
Genome-wide DNA methylation profiling was
conducted with Infinium HumanMethylation450 (450K)
BeadChips (Illumina). Genomic DNA (500 ng) was
bisulfite-converted using an EZ DNA Methylation Kit
(Zymo Research) and processed by UCL Genomics using
SOPs for hybridisation to 450K BeadChips, single-
nucleotide extension followed by immunohistochemistry
staining using a Freedom EVO robot (Tecan) and im-
aging using an iScan Microarray Scanner (Illumina). The
resulting data were quality controlled and analysed using
the ChAMP [26, 27] and minfi [28] analysis pipelines.
The 450K data have been deposited in ArrayExpress
under accession number E-MTAB-5377.
Smoking scores were generated using the method
developed by Elliott et al. [29]. The smoking score was
calculated using weighted methylation values of 187 well
established smoking-associated CpG sites [30] and has
been shown to accurately predict whether individuals
are past/never or current smokers [29]. This study
showed that a smoking score of more than 17.55 for Eu-
ropeans, or more than 11.79 for South Asians indicated
that an individual is a current smoker, while values
below these thresholds indicate that individuals are past
or never smokers. The threshold for classification of
smoking status in European populations was applied to
the smoking scores generated from both saliva and
blood samples for the PGP-UK pilot project.
Epigenetic age was calculated using the multi-tissue
Horvath clock [31], which uses the weighted average of
353 CpG sites associated with ageing to predict age and
has been extensively validated [32]. Age acceleration and
deceleration are calculated as the difference between
chronological age and epigenetic age. As the epigenetic
clock is accurate to within 3.6 years, individuals are
considered to have age acceleration if their epigenetic
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considered to have age deceleration if their epigenetic
age is > 3.6 years below their chronological age [31].
RNA sequencing (RNA-seq) was carried out on RNA
extracted from blood using both targeted and whole
RNA-seq. For targeted RNA-seq, library preparation was
carried out using AmpliSeq (Thermo Fisher Scientific).
A barcoded cDNA library was first generated with
SuperScript VILO cDNA Synthesis kit from 20 ng of
total RNA treated with Turbo DNase (Thermo Fisher
Scientific), followed by amplification using Ion Ampli-
Seq technology. Amplified cDNA libraries were
QC-analysed using Agilent Bioanalyzer high sensitivity
chips. Libraries were then diluted to 100 pM and
pooled equally, with two individual samples per pool.
Pooled libraries were amplified using emulsion PCR
on Ion Torrent OneTouch2 instruments (OT2)
following manufacturer’s instructions and then
sequenced on an Ion Torrent Proton sequencing
system, using Ion PI kit and chip version 2.
For whole RNA-seq, the libraries were prepared from
20 ng of total RNA with Illumina-compatible SENSE
mRNA-Seq Library Prep Kit V2 (Lexogen, NH, USA)
according to the manufacturer’s protocol. The resulting
double-stranded library was purified and amplified (18
PCR cycles) prior to adding the adaptors and indexes. The
final PCR product (sequencing library) was purified using
SPRI (Solid Phase Reversible Immobilisation) beads
followed by library quality control check, quantified using
Qubit fluorometer (Thermo Fisher Scientific) and
QC-analysed on Bioanalyzer 2100 (Agilent) and further
quantified by qPCR using KAPA library quantification kit
for Illumina (Kapa Biosystems). The libraries were se-
quenced on HiSeq 4000 (Illumina) for 150 bp paired-end
chemistry according to manufacturer’s protocol. The
average raw read per sample was 36,632,921 reads and the
number of expressed transcripts per sample was 25,182.
The RNA-seq data have been deposited in ArrayEx-
press under accession number E-MTAB-6523.Private variants
We define single nucleotide variants (SNVs) as private
(e.g. unique to individuals or families) in line with
ACMG standards and guidelines [33] if the variant has
not been recorded in any public database based on the
Beacon Network (https://beacon-network.org/) after
being corrected for batch effects. Such private SNVs
were then additionally filtered to be coding and analysed
with four orthogonal effect predictor methods CADD
[34]), DANN [35], FATHMM-MKL [36] and ExAC-pLI
[37] using default thresholds of 20, 0.95, 0.5 and 0.95,
respectively to identify private SNVs with the highest
possible confidence.Generation of reports
The genome reports were generated using variant calls
derived from the WGS data as described above. A whole
genome overview of the variant landscape of each partici-
pant was obtained by running the Variant Effect Predictor
(VEP) v84 [38] with hg19 (GRCh37) cache. The called
variants were interpreted in conjunction with public data
from SNPedia (as of 02-Aug-2018) [23], gnomAD v2.0.2
[37], GetEvidence (as of 10-Aug-2018) [10] and ClinVar
(as of 10-Aug-2018) [39] for potentially beneficial and po-
tentially harmful traits. A visual summary of the ancestry
of each participant was obtained by merging the genotypes
of each participant with genotypes from 2504 unrelated
samples from 26 worldwide populations from the 1000
Genomes Project (phase 3 v20130502) [40] and applying
principal component analysis on the merged genotype
matrix. Population membership proportions were inferred
using the Admixture v1.3.0 software [41] on the same
genotype matrix.
The methylome reports were generated from the 450K
data in conjunction with the epigenetic clock [31] for pre-
dictions on ageing and for predictions of exposure to
smoking [29].
Data access
All data reported here are available under open access
from the PGP-UK data web page (https://www.personal-
genomes.org.uk/data) which provides direct links to the
corresponding public databases. However, as it is in-
creasingly difficult to transfer data to the user, even
under open access, there is a growing need for the ana-
lytics to be moved to where the relevant data are being
stored. This concept is being addressed by cloud-based
computing platforms e.g. through public-private partner-
ships offering a variety of models from open to fee-based
data access [42–44], and easy access to training in big
data analytics such as the online DataCamp programme
[45]. Therefore, the reported PGP-UK data can also be
accessed free of charge for non-commercial use on the
Seven Bridges Cancer Genomics Cloud (CGC) [46],
where PGP-UK data are hosted alongside relevant ana-
lyses tools enabling researchers to compute over these
data in a cloud-based environment (see Links).
GenoME app
GenoME was developed as an educational app for Apple
iPads running iOS 9+. The app provides the public with a
means to explore and better understand personal genomes.
The app is fronted by four volunteer PGP-UK ambassa-
dors, who share their personal genome stories through em-
bedded videos and animated charts/information. All the
features within the app that illustrate ancestry, traits and
environmental exposures are populated by actual PGP-UK
data from the corresponding participants. GenoME is
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s.apple.com/gb/app/genome/id1358680703?mt=8).
Results
Data types and access options
To demonstrate the feasibility of citizen science-driven
contributions to personalized medicine, we actively
engaged the first 10 participants and first three Genome
Donors in all aspects of this PGP-UK pilot study. Table 1
summarizes the matrix of 9 types of information (WGS,
whole exome sequencing (WES), genotyping (e.g.
23andMe), 450K, WGBS, RNA-seq, Baseline Phenotypes,
Reports and GenoME) which was generated for six cat-
egories (genome, methylome, transcriptome, phenotype,
reports and GenoME app) and, where appropriate, the
biological source from which the information was derived.
The matrix comprises 103 datasets (~ 2.5 TB) which were
deposited according to data type in four different data-
bases (ENA, EVA, ArrayExpress and PGP-UK), as there
was no single public database able to host all data under
open access. While easy access is facilitated through the
PGP-UK data portal (see Links), the time required to
download all the data can present a challenge that is
common to many large-scale omics projects. The time to
download all the datasets from Table 1 using broadband
with UK national average download speed of 36.2Mbps
(according to official UK communication regulator
Ofcom, 2017) would be more than 140 h, indicating that
faster solutions are required. To address this, we joined
forces with Seven Bridges Genomics Inc. (SBG), a leading
provider of cloud-based computing infrastructure who
pioneered such a platform for The Cancer Genome Atlas
(TCGA). The Cancer Genomics Cloud (CGC, see Links)Table 1 Information matrix of the PGP-UK pilot study. Ticks [✔] indi
participants, the colour code depicts the biological source from whi
information provided via Genome Donations. Genotype data are fro
to whole-genome sequencing, WES to whole-exom sequencing, WG
HumanMethylation450 BeadChip.[46], funded as a pilot project by the US National Cancer
Institute (NCI), allows academic researchers to access and
collaborate on massive public cancer datasets, including
the TCGA data. Researchers worldwide can create a free
profile online or log in via their eRA Commons or NIH
Center for Information Technology account to gain access
to nearly 3 petabytes of publicly available data and rele-
vant tools to analyse them. Following a successful trial and
the open ethos of PGP, the data generated by the PGP-UK
consortium for the first 13 participants are now easily
accessible through the CGC for rapid, integrated and
scalable cloud-based analysis using publicly available or
custom-built pipelines.
Genome reports
While data are the most useful information for the wider
research community, reports were the most anticipated
and intelligible information for the PGP-UK participants
themselves. Great consideration was given to the content
and format of the reports, taking on board valuable feed-
back from individual participants and the entire pilot
group. At all times, the participants were made aware that
both the data and reports were for information and re-
search use only and not clinically accredited or actionable.
For the reporting of genetic variants, we opted for
strict criteria so that the reported variants are low in
number but as informative as possible (see Methods).
On average, this resulted in over 200 incidental variants
being reported for possibly beneficial and harmful traits.
Additional file 1 shows an exemplar genome report for
participant uk35C650. In total, 4,105,373 SNVs were
identified of which 97.5% were known and 2.5% (103,667
SNVs) appeared to be novel and thus private to thiscate the types of information available for each of the
ch the information was derived and boxing highlights the
m 23andMe but other formats can also be donated. WGS refers
BS to whole-genome bisulfite sequencing and 450K to Infinium
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participants sequenced by PGP-UK, which is consistent
with previous findings [40]. Of the known variants of
participant uk35C650, 63 were associated with possibly
beneficial traits (e.g. 9 SNVs associated with higher levels
of high density lipoprotein (HDL) which is the ‘good’
type of cholesterol) and 217 with possibly harmful traits
(e.g. 14 SNVs associated with Crohn’s disease, according
to previously published studies). Taking advantage again
of the open nature of PGP-UK, we shared the reports
among all 10 participants, which helped them to better
understand the concept and meaning of beneficial or
harmful SNV frequencies and distributions in the popu-
lation. Since any genome report has the potential to un-
cover unexpected and even disconcerting information,
the opportunity for participants to view other reports
alongside their own provides context and reduces the
likely anxiety if such reports are received and viewed in
isolation. This was indeed confirmed as a positive aspect
by all participants in the pilot study. In addition to learn-
ing about possibly beneficial and harmful variants, the
participants were also interested to learn more about the
‘novel’ and potentially ‘private’ variants for which, by
definition, nothing is yet known. This prompted us to
investigate them in more detail.Private variants
A definition of what we consider private variants is de-
scribed in the Methods section. Additional file 2 shows
the number of all, novel and private SNVs identified in 10
of the participants using the PGP-UK analysis pipeline
and additional, more stringent filtering against all openly
accessible resources (see Methods). While this approach is
imperfect due to some variants being represented in23890
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ExAC pLI
Fig. 1 Venn diagram of private SNVs from the 10 PGP-UK pilot participants
orthogonal prediction methods indicated. See Abbreviations section for dedifferent ways and therefore easily missed [47], this effort
reduced the number SNVs that are likely to be private to
< 20,000 per participant on average. To obtain a first
insight into their possible functions we used multiple
independent methods (see Methods and Additional file 2)
to predict their effects. Of the 177,804 private SNVs iden-
tified, 29,558 (16.6%) passed the detection thresholds de-
scribed in Methods and Additional file 3. As private SNVs
cannot be validated in the traditional way, we used a Venn
diagram (Fig. 1) to assess the level of concordance/dis-
cordance between the four orthologous methods used.
Fourty seven SNVs were predicted to have significant im-
pact by all four methods (Fig. 1), providing the highest
level of confidence that these are novel SNVs affecting
gene function. Finally, we mapped these 47 private SNVs
to their respective coding exons to reveal the affected
genes (Additional file 4). The majority (41 SNVs) were
predicted to have moderate impact, one was predicted to
have high impact and four were predicted to have a modi-
fier impact (Additional file 4). See Definitions section for
descriptions of moderate, high and modifier impact.
Methylome reports
There are currently no national or international policies or
guidelines in place for the reporting of incidental epigen-
etic findings, including those based on DNA methylation
[48, 49]. We limited our reports to categories for which
findings had been independently validated and replicated,
including the prediction of sex [31, 50], age [31] and
smoking status [51]. Additional file 5 shows an exemplar
methylome report and Additional file 6 summarizes our re-
ported incidental epigenetic findings for the participants of
the PGP-UK pilot. While the current methods for predic-
tion of chronological age and sex are already well estab-
lished and were highly accurate for all participants2281
44
136
2
30
323
DANN
FATHMM−MKL
. Only coding SNVs were selected for effect prediction using the four
scription of acronyms
Fig. 2 Time series (a-c) of screens showing how GenoME
communicates genetic SNVs associated with the participant’s eye
colour. PGP-UK participant uk35C650 self-identified and consented
for his photos to be used
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ate prediction and interpretation of age deviation are still
experimental. Averaged over two samples of different ori-
gin (blood and saliva), three of the thirteen participants
showed significant age acceleration whereby the DNA
methylation age is higher than the actual (chronological)
age by more than 3.6 years, and three showed age deceler-
ation (DNA methylation age is lower than the actual age
by more than 3.6 years). Age deviation has already proved
to be an informative biomarker. For instance, age acceler-
ation has been reported to predict all-cause mortality in
later life [52, 53] as well as cancer risk [54] and age deceler-
ation has been linked to longevity [55, 56].
The final category which was reported back to partici-
pants was exposure to smoking. Epigenetic associations
with environmentally mediated exposures are typically
measured through epigenome-wide association studies
(EWAS) [57]. Based on the analysis of DNA methylation in
saliva and blood samples, all participants in the PGP-UK
pilot study were predicted to be past or never smokers.
The prediction was correct for 12 out of the 13 participants
who self-reported as either past or never smokers. How-
ever, one participant (uk0C72FF) self-reported as an ‘occa-
sional smoker’. This aberrant prediction could be explained
by the study population in which the threshold was set; the
individuals considered ‘current smokers’ smoked a mean of
23 cigarettes per day for Europeans and 13 per day for
South Asians. Consequently, very occasional smoking may
not classify as ‘current smoking’ using the thresholds of El-
liott et al. [29]. Another limitation is that the smoking score
was tested in European and South Asian populations, thus
it may be less accurate in other ethnicities.
GenoME app
To make genome and methylome reports more access-
ible and understandable to the lay public, we developed
GenoME as a free and open source genome app for
Apple iPads. The main purpose was to have actual
people presenting real incidental findings in an innova-
tive and engaging way. For that, we recruited four volun-
teers (ambassadors) from the pilot cohort who were
willing to self-identify and share their personal genome
story through embedded videos, specifically composed
music and artistically animated examples of incidental
findings from their genomes. To illustrate this, we
selected two traits (eye colour and smoking status) for
which we reported genetic and epigenetic variants,
respectively. Figure 2 shows three screen shots of how
SNVs associated with eye colour are communicated.
Figure 2a shows one of the ambassadors and explanatory
text in the left panel and a whirling cloud of colour repre-
senting all possible eye colours in the right panel. Figure
2b shows an intermediate state of the colours coalescing
into the eye colour predicted by the SNVs for thisparticipant and Fig. 2c shows the final stage of zooming
in on the ambassador’s actual eye colour for comparison
with the predicted eye colour which was correct in this
case. In GenoME, the sequence of screens is
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people with compromised sight to experience genetic vari-
ation through sound. Figure 3 shows a similar sequence of
three screens for the prediction smoking status based onFig. 3 Time series (a-c) of screens showing how GenoME
communicates epigenetic SNVs associated with the participant’s
smoking status. PGP-UK participant uk35C650 self-identified and
consented for his photos to be usedepigenetic (DNA methylation) variants. In this case, a
cloud of smoke coalesces into ‘never/past’ or ‘current’
smoker icons depending on the epigenetic profile of the
participant. Other features (not shown) include variants
associated with ancestry using an animated world map
and disease using population-specific allele frequency
graphics.
Discussion
In this study, we report the study design, data processing
and findings of the PGP-UK pilot, and demonstrate the
suitability of PGP-UK as a hybrid between a research
and a citizen science project. For the latter, we enlisted 11
citizen scientists who made up a third of the named
authors and contributed vitally to the assessment of our
reporting strategy, features of GenoME and advocacy of
citizen science in general. As part of our citizen science
programme, PGP-UK encourages such interactions also
on the international level through membership of the glo-
bal PGP Network, DNA. Land [58] and Open Humans
(see Links), a project which enables individuals to connect
their data with research and citizen science worldwide.
The resource value of PGP-UK will become more
apparent as more participants are enrolled and data
released. Towards this, a second batch of data and
reports has already been released (see Links) for another
94 participants and the ultimate goal is to eventually
reach the 100 K participants mark for which ethics
approval has been obtained. Considering the scale of
past and on-going UK sequencing projects [4, 59], we
believe this is achievable especially though utilizing the
genome donation procedure described here. In the
meantime, the PGP-UK data also contribute to the glo-
bal PGP resource. According to Repositive (see Links), a
platform linking open access data across 49 resources,
the global PGP network has collectively generated over
1,121 data sets. Additionally and in the N = 1 context of
personalised medicine, each data set is of course highly
informative in its own right [60].
To our knowledge, the methylome reports described
here are the first of their kind issued for any incidental
epigenetic findings. The open nature of PGP-UK makes
it possible to explore appropriate frameworks and guide-
lines in a controlled environment [48, 49]. Based on our
experience, there is high interest and acceptance for
adequately validated and replicated epigenetic findings
to be reported back alongside genetic findings, particu-
larly those that capture environmental exposures such as
tobacco smoke, alcohol consumption and air pollution.
Accordingly, we are now evaluating if any EWAS-derived
variants are yet appropriate for inclusion. Another area of
potential future interest is the prediction of a participant’s
suitability as donor in the context of transplant medicine
[61]. Another innovation reported here is GenoME, an
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millions of people and thus are an ideal stepping-stone to
engage with citizen science, which plays an important role
in making personal and medical genomics acceptable to
the public. A recent study – Your DNA, Your Say – con-
cluded that “Genomic medicine can only be successfully in-
tegrated into healthcare if there are aligned programmes of
engagement that enlighten the public to what genomics is
and what it can offer” [62]. This is particularly important
as we reach the cusp of widespread implementation of
genomic and personalised medicine. To gauge the level
and types of possible concerns or problems experienced
by participants as result of their participation in PGP-UK,
our tracking system automatically prompts them for feed-
back twice a year. So far, we have received 1423 responses
of which 1414 (99.3%) had nothing to report. Of the nine
participants who did file a report, four reported interest
expressed by family members and friends, three reported
personal health-related problems and two simply ac-
knowledged having been contacted. None of the 103 par-
ticipants (including the 13 pilot participants) who have
received their genome reports have filed a report or with-
drawn consent. Of the 1105 participants who were so far
allowed to consent and enrol, seven have withdrawn their
consent and participation, five stating no reason, one stat-
ing too long waiting time as reason and one stated change
of mind. Prior to the enrolment opening, PGP-UK experi-
enced an email incident in 2014 which tested the resolve
of those who had expressed interest in participating in an
open project like PGP-UK.
Our study also highlighted some limitations. For in-
stance, adequate public databases for multi-dimensional
open access data, equivalent to dbGaP [63] or EGA [64]
for controlled access data, are currently still lacking.
Consequently, the PGP-UK data were submitted to
multiple open access public databases, depending on
type of data. Furthermore, most public databases are
not built to host or enable downloading of TB-scale
datasets and don’t enable easy access and analysis
without downloading the data. To overcome these
current limitations, we made the PGP-UK pilot data
also available in a cloud-based system [46]. The high
level of automation implemented for the PGP-UK
analysis pipeline allows updates to be generated and
released as and when required and new reports (e.g.
based on WGBS and RNA-seq data) to be added in
the future. At the time of submission, over 100
genomes and associated reports had been generated,
released (see Links) and deposited into public
databases.
Conclusion
Our results demonstrate that omics-based research and
citizen science can be successfully hybridised into anopen access resource for personal and medical genomics.
The key features that allowed this were transparency
and interoperability on the people and data levels, result-
ing in a degree of openness that is not generally found
in medical research and thus provides an alternative to
traditional research models. The introduction of the
GenoME app and the framework for Genome Donations
provide two novel modes for the public to engage with
personal and medical genomics.
Definitions
 Open access: Mode of access to data that are freely,
publicly and directly accessible under a CC0 waiver
or equivalent public domain license.
 Registered access: Mode of access to data that are
freely but not publically and directly available using
a single three-stage approval process for authentica-
tion, attestation and authorization.
 High impact variant consequence: The Variant is
assumed to have high (disruptive) impact in the
protein, probably causing protein truncation, loss of
function or triggering nonsense mediated decay (See
Links, Ensembl glossary).
 Moderate impact variant consequence: A non-
disruptive variant that might change protein effect-
iveness (See Links, Ensembl glossary).
 Modifier impact variant consequence: Usually
non-coding variants or variants affecting non-coding
genes, where predictions are difficult or there is no
evidence of impact (See Links, Ensembl glossary).
Additional files
Additional file 1: Exemplar PGP-UK genome report of participant
uk35C650 providing details on the number and type of variants and their
association with ancestry as well as possibly beneficial and harmful traits.
The released versions of the reports provide links to the underlying data-
bases, including SNPedia, gnomAD, GetEvidence and ClinVar. (PDF 203 kb)
Additional file 2: Number of all, novel and private SNVs identified in
the 10 PGP-UK pilot participants. Private SNVs were further analysed by
four orthogonal methods for functional effects and the listed numbers
reflect those SNVs that passed the thresholds described in Methods and
Additional file 3. (XLSX 20 kb)
Additional file 3: Distribution of private SNVs following effect prediction
with multiple methods. SNVs that passed the significance threshold for
each method are coloured red. (ZIP 144 kb)
Additional file 4: Genes predicted to be affected by private SNVs
identified in the PGP-UK pilot. (XLSX 32 kb)
Additional file 5: Exemplar PGP-UK 450K methylome report of partici-
pant uk35C650 providing predictions for sex, age and smoking status
using blood or saliva as indicated. (PDF 223 kb)
Additional file 6: Summary of 450K methylome predictions for ten
participants and three genome donations (boxed) of the PGP-UK pilot
study. Predictions were made for sex, age and smoking status using
blood or saliva as indicated. Asterisks (*) denote that methylation age
acceleration and deceleration is only present if methylation age is more
than 3.6 years different to the respective actual age [53]. (XLSX 21 kb)
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450K: Infinium HumanMethylation450 BeadChip; CADD: Combined
Annotation Dependent Depletion; DANN: Deleterious Annotation of genetic
variants using Neural Networks; EWAS: Epigenome-wide association study;
ExAC-pLI: Probability of being Loss-of-Function (LoF) Intolerant (based on
data from the Exome Aggregation Consortium (ExAC)); FATHMM-MKL: Functional
Analysis Through Hidden Markov Models; PGP-UK: Personal Genome Project UK;
SNV: Single nucleotide variant; WGBS: Whole-genome bisulfite sequencing;
WGE: Whole-exome sequencing; WGS: Whole-genome sequencing
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